QLQian Li

Qian Li

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Qian Li has a total of 5 co-authors. Here are the top co-authors by number of shared publications:

  • Dan-Lei Xiong

    School of Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, 310018, People’s Republic of China

    1 shared publication
  • Heng Wang

    Graduate Department, Bengbu Medical College, Bengbu, Anhui, 233000, People’s Republic of China

    1 shared publication
  • Wei-Li Jin

    Department of Gastroenterology, Nanxun People’s Hospital (Zhejiang Provincial People’s Hospital Nanxun Branch), Huzhou, 313009, Zhejiang Province, People’s Republic of China

    1 shared publication
  • Xiao-Ming Fan

    Cancer Center, Department of Ultrasound Medicine, Zhejiang Provincial People’s Hospital (Affiliated People’s Hospital, Hangzhou Medical College), Hangzhou, 310014, People’s Republic of China

    1 shared publication
  • Ying-Yu Ma

    Department of Neurosurgery, Cancer Center, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, Zhejiang 310014, P.R. China

    1 shared publication

Latest Publications

  • Open Access

    High Expression of SLC41A3 Correlates with Poor Prognosis in Hepatocellular Carcinoma

    by Qian Li, Dan-Lei Xiong, Heng Wang, Wei-Li Jin, Ying-Yu Ma, Xiao-Ming Fan

    Purpose: SLC41A3 is a member of the solute carrier family 41 (SLC41) and is involved in many cellular processes as a magnesium ion transporter. Although it plays an important role in cancer formation and development, the correlation between the expression of SLC41A3 and the occurrence and prognosis of hepatocellular carcinoma (HCC) remains unclear. Therefore, this study was focused on the evaluation of the relationship between SLC41A3 and the development and prognosis of HCC. Patients and Methods: Firstly, we collected the mRNA expression of SLC41A3 in HCC through the platform of Oncomine. Then, the subgroups of HCC were performed by the UALCAN website and the prognosis of HCC was analyzed by Kaplan–Meier Plotter database. Subsequently, immunohistochemistry (IHC) method was used to detect SLC41A3 expression in 323 clinically confirmed HCC samples and 184 non-cancerous liver tissues. Finally, function enrichment analysis was done using the LinkInterpreter module in LinkedOmics, and gene set enrichment analysis (GSEA) was performed using TCGA data set. Results: The Oncomine database and immunohistochemical (IHC) showed higher SLC41A3 expression in HCC tissue compared to normal tissue. The expression of SLC41A3 was significantly correlated with tumor metastasis, Edmondson grade, microvascular invasion, and AFP level. Kaplan–Meier and Cox regression analyses verified that high SLC41A3 expression is a significant prognostic factor for reduced overall survival in HCC patients. Conclusion: Our results demonstrated that high expression of SLC41A3 was the predictor of poor prognosis in HCC patients, suggesting that this protein may be a potential target for HCC therapy.